Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
$0.66
$0.74
$0.55
$4.56
$16.15MN/AN/A574,675 shs
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
$2.97
+1.7%
$2.34
$1.26
$3.12
$82.79M0.24153,736 shs278,471 shs
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$14.07
-0.1%
$9.14
$6.53
$29.40
$122.86M2.75129,203 shs85,712 shs
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
$3.89
+4.6%
$2.99
$1.14
$7.47
$120.49M1.95513,462 shs320,616 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
0.00%0.00%0.00%0.00%0.00%
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
+1.71%+12.08%+24.27%+78.92%+36.24%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-0.07%+11.93%+82.02%+90.14%-52.47%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
+4.57%-2.26%+81.78%+171.08%-38.35%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
3.1196 of 5 stars
3.55.00.00.00.03.30.6
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
2.9011 of 5 stars
2.91.00.04.61.10.80.0
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
1.7732 of 5 stars
3.54.00.00.01.10.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
0.00
N/AN/AN/A
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
3.00
Buy$7.00135.69% Upside
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
1.75
Reduce$73.67423.57% Upside
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
3.00
Buy$16.60326.74% Upside

Current Analyst Ratings Breakdown

Latest ACER, SKYE, MCRB, and IMMX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$15.00
6/4/2025
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00
5/20/2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
5/8/2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$1.25 ➝ $6.00
(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
N/AN/AN/AN/AN/AN/A
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
N/AN/AN/AN/A$0.48 per shareN/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$126.32M0.97N/AN/A$1.61 per share8.74
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/A$2.25 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
-$26.24MN/A0.00N/AN/AN/AN/AN/A
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
-$21.61M-$0.70N/AN/AN/AN/A-130.02%-86.33%8/11/2025 (Estimated)
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$140K-$4.60N/AN/AN/AN/A-41,084.76%-55.87%8/12/2025 (Estimated)
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$26.57M-$0.82N/AN/AN/AN/A-53.92%-48.58%N/A

Latest ACER, SKYE, MCRB, and IMMX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-$2.72N/AN/AN/AN/AN/A
8/11/2025Q1 2025
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
-$0.21N/AN/AN/AN/AN/A
5/8/2025Q1 2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$0.31-$0.28+$0.03-$0.28N/AN/A
5/7/2025Q1 2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-$0.67-$2.24-$1.57$3.75$10.00 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
N/AN/AN/AN/AN/A
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
N/AN/AN/AN/AN/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/AN/AN/AN/AN/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
N/AN/AN/A
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
N/A
1.80
1.80
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/A
2.11
2.11
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/A
11.85
11.85

Institutional Ownership

CompanyInstitutional Ownership
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
N/A
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
11.26%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
59.34%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
21.09%

Insider Ownership

CompanyInsider Ownership
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
20.20%
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
55.40%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
4.70%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
4.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acer Therapeutics Inc. stock logo
ACER
Acer Therapeutics
3024.46 million19.52 millionNot Optionable
Immix Biopharma, Inc. stock logo
IMMX
Immix Biopharma
927.88 million12.43 millionOptionable
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
3308.73 million8.32 millionOptionable
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
1130.98 million29.58 millionOptionable

Recent News About These Companies

SKYE Stock Price Quote | Morningstar
Skye Bioscience, Inc. (SKYE) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Acer Therapeutics stock logo

Acer Therapeutics NASDAQ:ACER

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts.

Immix Biopharma stock logo

Immix Biopharma NASDAQ:IMMX

$2.97 +0.05 (+1.71%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$2.91 -0.06 (-2.02%)
As of 07/18/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Seres Therapeutics stock logo

Seres Therapeutics NASDAQ:MCRB

$14.07 -0.01 (-0.07%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$14.80 +0.73 (+5.22%)
As of 07/18/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Skye Bioscience stock logo

Skye Bioscience NASDAQ:SKYE

$3.89 +0.17 (+4.57%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$3.92 +0.03 (+0.77%)
As of 07/18/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.